CytoSorbents Reports Third Quarter 2026 Financial Results, Achieves Operating Cash Flow Breakeven, and Provides Business and Regulatory Update

Résumé détaillé

Delivering on the First of Four Distinct Value Drivers PRINCETON, N.J., Nov. 12, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of…

PRINCETON, N.J., Nov. 12, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the third quarter ended September 30, 2026, recent business highlights, and provides a regulatory update.

"The third quarter marked an important financial milestone for CytoSorbents as we achieved our goal of operating cash flow breakeven, excluding restructuring-related payments," stated Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. "This achievement reflects a year of disciplined execution and meaningful improvements in our underlying business. Product gross margin expanded to 75%, operating expenses declined 11%, operating loss improved 59%, and notably, adjusted EBITDA loss narrowed 86% to approximately $0.3 million. These results demonstrate the impact of our more efficient cost structure and position us to benefit from improved operating leverage as revenue grows.

Progress on Our Four Distinct Value Drivers"We continue to advance four distinct value drivers, each with the potential to create meaningful shareholder value. These include achieving sustainable operating cash flow breakeven, restoring profitable growth in our core CytoSorb business, opening the U.S. market through DrugSorb-ATR, and unlocking the strategic value of HemoDefend-BGA. With our first milestone achieved, we are focused on sustaining this progress while advancing the remaining three opportunities.

First Value Driver: Achieving Operating Cash Flow Breakeven — Achieved in Q3 2026"In the third quarter, we generated approximately $43,000 in positive operating cash flow, excluding $251,000 in restructuring-related payments, compared with operating cash burn of approximately $200,000 in Q2 2026 on the same basis and $2.7 million in Q3 2025.

"This improvement reflects a broad-based effort to optimize our operations.

"Our focus now turns…

Début de l'article, extrait de PR Newswire. Pour lire la suite, ouvrez l'article chez le média.